Why CardioHemeRISK™ For Cardiac Screening?
Heart disease often develops silently over many years. Traditional tests detect risk factors such as cholesterol levels, blood pressure, or existing arterial plaque. But by the time plaque forms or arteries are damaged, the disease process may already be well underway.
CardioHemeRISK is a blood test that detects clonal hematopoiesis-related mutations and helps physicians understand hidden risks to heart and blood health earlier. This information can help guide preventive strategies, lifestyle changes, and monitoring.
Speak to your healthcare provider to seek advice on your options.
Many serious health conditions can strike without warning.
1 in 4
heart attack patients have
no known risk factors [1]
1 in 5
stroke patients have
no known risk factors [2]
1 in 3
leukemia cases are diagnosed
in the emergency room [3]
CardioHemeRISK is a next-generation sequencing (NGS) blood test. The test detects clonal hematopoiesis (CH) mutations using Lucence's mirror barcoding technology.
This is a prescription only screening test.
CardioHemeRISK does not diagnose heart attack, stroke, or leukemia. Further confirmatory testing is recommended for positive results.
What is CH?
Clonal hematopoiesis (CH) is a common disorder acquired as an age- and lifestyle-related inflammatory process.
It starts typically above age 40 when one blood stem cell develops a mutation and begins making lots of blood cells (clonal expansion) with the same mutation. It is not cancer.
.png)
Compared to the general population, individuals with CH mutations have a greater risk of:
12x
Heart Attack [4]
3.1x
Stroke [5]
12.9x
Leukemia [6]
CardioHemeRISK is recommended for:
-
Healthy individuals aged above 40 and below 80
-
Cancer survivors previously treated with chemotherapy or radiation
-
Individuals with history of atherosclerotic disease such as coronary artery disease or ischemic stroke
-
Healthy individuals aged above 40 with additional risk factors for atherosclerotic disease such as family history, hypertension, hyperlipidemia
Downloads
Specifications
Single Nucleotide Variants (SNVs)
>92%
Sensitivity
>99%
Specificity
0.05%
LOD
Insertions / Deletions (indels)
>91%
Sensitivity
>99%
Specificity
0.05%
LOD
References:
-
Paul, G. et al. Global Heart 2023; 18(1): doi: 10.5334/gh.1189.
-
Beharry, J. et al. Eur Stroke J 2025; doi: 10.1177/23969873241309516.
-
Leukaemia Care. Leukaemia UK. Published September 4, 2022. Accessed May 2, 2025. https://www.leukaemiauk.org.uk/news/worrying-numbers-ofleukaemia-patients/.
-
Jaiswal, S. et al. N Engl J Med 2017; 377(2): 111-121. PMID: 28636844. Early onset myocardial infarction: HR = 12; 95% CI, 3.8–38; P < 0.001.
-
Jaiswal, S. et al. N Engl J Med 2014; 371(26): 2488-2498. PMID: 25426837. Ischemic stroke: HR = 3.1; 95% CI, 1.2–8.4; P = 0.025.
-
Genovese, G. et al. N Engl J Med 2014; 371: 2477-2487. PMID: 25426838. Hematologic cancer: HR = 12.9; 95% CI, 5.8–28.7; P < 0.001.
